Abstract: Some embodiments of the present disclosure relate to an roofing shingle comprising a low penetration point asphalt reinforced glass mat. In some embodiments, the reinforced glass mat comprises a glass mat and a reinforcement material. In some embodiments, the glass mat comprises a web of glass fibers. In some embodiments, the reinforcement material is embedded into the web of glass fibers of the glass mat. In some embodiments, the reinforced glass mat comprises a sufficient amount of the reinforcement material, so as to result in a nail shank shear resistance of 13 lbs to 17 lbs, according to ASTM 1761 at 140° F. Methods of making the roofing shingle and methods of forming a roofing shingle from the roofing shingle are also disclosed herein.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof based on results from long term clinical studies.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The system and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment are disclosed. In one embodiment, the system monitors and tracks certain variables at several levels (e.g., firm, trader, trade desk, symbol, side, order type) for each participant in the system, updates the values of the variables in real time and/or over longer periods. From the values of the variables, the system assigns individual and composite scores to each trader, symbol or side or any composite of these and other variables. For every interaction in the trading environment, the scores and variables are used to determine how a trader interacts with a contra trader when their respective scores are compared, including determining permissioning and timing of sending invitations to trade, permissioning and timing of receiving invitations to trade and/or execution of the trade.

Abstract: There is disclosed apparatus and methods for providing a reserve power source for a ventricular assist device. In an embodiment, the apparatus includes a primary power source for powering the device, and a controller housing having a reserve battery for powering the device when the primary power source provides inadequate power, and the controller housing configured for use externally of the patient with a percutaneous cable to the device. In another embodiment, a method includes powering the device with a primary power source, monitoring power provided to the device, powering the device when the power is monitored as inadequate to the device with a reserve power source disposed within a controller housing, the device disposed subcutaneously within a patient, the controller housing disposed externally of the patient, and the device and the controller housing connected by a percutaneous cable. Other embodiments are also disclosed.

Abstract: There is disclosed apparatus and methods for providing a reserve power source for a ventricular assist device. In an embodiment, the apparatus includes a primary power source for powering the device, and a controller housing having a reserve battery for powering the device when the primary power source provides inadequate power, and the controller housing configured for use externally of the patient with a percutaneous cable to the device. In another embodiment, a method includes powering the device with a primary power source, monitoring power provided to the device, powering the device when the power is monitored as inadequate to the device with a reserve power source disposed within a controller housing, the device disposed subcutaneously within a patient, the controller housing disposed externally of the patient, and the device and the controller housing connected by a percutaneous cable. Other embodiments are also disclosed.

Abstract: There is disclosed apparatus and methods for providing a reserve power source for a ventricular assist device. In an embodiment, the apparatus includes a primary power source for powering the device, and a controller housing having a reserve battery for powering the device when the primary power source provides inadequate power, and the controller housing configured for use externally of the patient with a percutaneous cable to the device. In another embodiment, a method includes powering the device with a primary power source, monitoring power provided to the device, powering the device when the power is monitored as inadequate to the device with a reserve power source disposed within a controller housing, the device disposed subcutaneously within a patient, the controller housing disposed externally of the patient, and the device and the controller housing connected by a percutaneous cable. Other embodiments are also disclosed.